GSK plc announced that the FDA accepted its application for Blenrep in combinations for relapsed/refractory multiple myeloma, based on trials showing significant efficacy. The FDA's decision is expected by July 23, 2025.
AI Assistant
GSK PLC
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.